Published in Am J Pathol on October 01, 2005
Genetics of HUS: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome. Blood (2006) 4.51
Structural basis for engagement by complement factor H of C3b on a self surface. Nat Struct Mol Biol (2011) 2.32
Leptospira interrogans endostatin-like outer membrane proteins bind host fibronectin, laminin and regulators of complement. PLoS One (2007) 1.74
Structure of complement factor H carboxyl-terminus reveals molecular basis of atypical haemolytic uremic syndrome. EMBO J (2006) 1.72
The binding of factor H to a complex of physiological polyanions and C3b on cells is impaired in atypical hemolytic uremic syndrome. J Immunol (2009) 1.70
A novel targeted inhibitor of the alternative pathway of complement and its therapeutic application in ischemia/reperfusion injury. J Immunol (2008) 1.70
Complement control protein factor H: the good, the bad, and the inadequate. Mol Immunol (2010) 1.68
Genetics and complement in atypical HUS. Pediatr Nephrol (2010) 1.64
Dual interaction of factor H with C3d and glycosaminoglycans in host-nonhost discrimination by complement. Proc Natl Acad Sci U S A (2011) 1.58
Atypical hemolytic uremic syndrome. Semin Nephrol (2013) 1.56
Translational mini-review series on complement factor H: structural and functional correlations for factor H. Clin Exp Immunol (2008) 1.52
The C-terminus of complement regulator Factor H mediates target recognition: evidence for a compact conformation of the native protein. Clin Exp Immunol (2006) 1.50
Mutations of factor H impair regulation of surface-bound C3b by three mechanisms in atypical hemolytic uremic syndrome. J Biol Chem (2009) 1.21
Factor H mediated cell surface protection from complement is critical for the survival of PNH erythrocytes. Blood (2007) 1.16
Structure of the N-terminal region of complement factor H and conformational implications of disease-linked sequence variations. J Biol Chem (2008) 1.16
Disease-associated N-terminal complement factor H mutations perturb cofactor and decay-accelerating activities. J Biol Chem (2011) 1.15
The C-terminus of complement factor H is essential for host cell protection. Mol Immunol (2007) 1.14
Complement regulator Factor H mediates a two-step uptake of Streptococcus pneumoniae by human cells. J Biol Chem (2010) 1.13
Microbes bind complement inhibitor factor H via a common site. PLoS Pathog (2013) 1.06
Progress in defining the molecular biology of age related macular degeneration. Hum Genet (2007) 1.01
Lyme borreliosis spirochete Erp proteins, their known host ligands, and potential roles in mammalian infection. Int J Med Microbiol (2008) 1.00
Complement in glomerular injury. Semin Immunopathol (2007) 0.99
Factor h: a complement regulator in health and disease, and a mediator of cellular interactions. Biomolecules (2012) 0.99
Decidual endothelial cells express surface-bound C1q as a molecular bridge between endovascular trophoblast and decidual endothelium. Mol Immunol (2008) 0.97
Factor H and neisserial pathogenesis. Vaccine (2008) 0.96
What's new in haemolytic uraemic syndrome? Eur J Pediatr (2008) 0.91
Complement factor H-related proteins CFHR2 and CFHR5 represent novel ligands for the infection-associated CRASP proteins of Borrelia burgdorferi. PLoS One (2010) 0.90
Properdin: a tightly regulated critical inflammatory modulator. Immunol Rev (2016) 0.85
Molecular characterization of the interaction between sialylated Neisseria gonorrhoeae and factor H. J Biol Chem (2011) 0.83
Review: Complement and its regulatory proteins in kidney diseases. Nephrology (Carlton) (2010) 0.82
Dynamic control of the complement system by modulated expression of regulatory proteins. Lab Invest (2010) 0.80
Comparative proteomic analysis of serum from patients with systemic sclerosis and sclerodermatous GVHD. Evidence of defective function of factor H. PLoS One (2010) 0.80
Properdin has an ascendancy over factor H regulation in complement-mediated renal tubular damage. BMC Nephrol (2014) 0.78
Retracted Insights into the Effects of Complement Factor H on the Assembly and Decay of the Alternative Pathway C3 Proconvertase and C3 Convertase. J Biol Chem (2016) 0.76
The Murine Factor H-Related Protein FHR-B Promotes Complement Activation. Front Immunol (2017) 0.75
ISOLATION OF BETA IF-GLOBULIN FROM HUMAN SERUM AND ITS CHARACTERIZATION AS THE FIFTH COMPONENT OF COMPLEMENT. J Exp Med (1965) 15.47
Human complement C3b inactivator: isolation, characterization, and demonstration of an absolute requirement for the serum protein beta1H for cleavage of C3b and C4b in solution. J Exp Med (1977) 7.89
Modulation of the alternative complement pathways by beta 1 H globulin. J Exp Med (1976) 7.00
Control of the amplification convertase of complement by the plasma protein beta1H. Proc Natl Acad Sci U S A (1976) 6.65
Regulation by membrane sialic acid of beta1H-dependent decay-dissociation of amplification C3 convertase of the alternative complement pathway. Proc Natl Acad Sci U S A (1978) 4.43
Uncontrolled C3 activation causes membranoproliferative glomerulonephritis in mice deficient in complement factor H. Nat Genet (2002) 4.22
Genetic studies into inherited and sporadic hemolytic uremic syndrome. Kidney Int (1998) 4.03
Antiphagocytic activity of streptococcal M protein: selective binding of complement control protein factor H. Proc Natl Acad Sci U S A (1988) 3.82
The complement regulator factor H binds to the surface protein OspE of Borrelia burgdorferi. J Biol Chem (2000) 3.24
A novel sialic acid binding site on factor H mediates serum resistance of sialylated Neisseria gonorrhoeae. J Exp Med (1998) 3.03
Mutations in factor H reduce binding affinity to C3b and heparin and surface attachment to endothelial cells in hemolytic uremic syndrome. J Clin Invest (2003) 2.96
Factor H mutations in hemolytic uremic syndrome cluster in exons 18-20, a domain important for host cell recognition. Am J Hum Genet (2001) 2.92
Activation of the alternative complement pathway with rabbit erythrocytes by circumvention of the regulatory action of endogenous control proteins. J Exp Med (1977) 2.87
The covalent-binding reaction of complement component C3. Biochem J (1981) 2.80
Discrimination between activators and nonactivators of the alternative pathway of complement: regulation via a sialic acid/polyanion binding site on factor H. Proc Natl Acad Sci U S A (1990) 2.79
The molecular basis of familial hemolytic uremic syndrome: mutation analysis of factor H gene reveals a hot spot in short consensus repeat 20. J Am Soc Nephrol (2001) 2.56
Heterozygous and homozygous factor h deficiencies associated with hemolytic uremic syndrome or membranoproliferative glomerulonephritis: report and genetic analysis of 16 cases. J Am Soc Nephrol (2004) 2.46
Thrombotic microangiopathy, hemolytic uremic syndrome, and thrombotic thrombocytopenic purpura. Kidney Int (2001) 2.43
Structural and functional characterization of factor H mutations associated with atypical hemolytic uremic syndrome. Am J Hum Genet (2002) 2.29
Complement resistance of Borrelia burgdorferi correlates with the expression of BbCRASP-1, a novel linear plasmid-encoded surface protein that interacts with human factor H and FHL-1 and is unrelated to Erp proteins. J Biol Chem (2003) 1.99
Identification of the second heparin-binding domain in human complement factor H. J Immunol (1998) 1.92
Haemolytic uraemic syndrome and mutations of the factor H gene: a registry-based study of German speaking countries. J Med Genet (2003) 1.92
Identification of three physically and functionally distinct binding sites for C3b in human complement factor H by deletion mutagenesis. Proc Natl Acad Sci U S A (1996) 1.91
Comprehensive analysis of the factor h binding capabilities of borrelia species associated with lyme disease: delineation of two distinct classes of factor h binding proteins. Infect Immun (2003) 1.86
Familial hemolytic uremic syndrome associated with complement factor H deficiency. J Pediatr (2001) 1.84
Each of the three binding sites on complement factor H interacts with a distinct site on C3b. J Biol Chem (2000) 1.82
Localization of the heparin-binding site on complement factor H. J Biol Chem (1991) 1.77
Identification of a heparin binding domain in the seventh short consensus repeat of complement factor H. J Immunol (1996) 1.68
Activation of the alternative complement pathway: recognition of surface structures on activators by bound C3b. J Immunol (1980) 1.65
Complement resistance mechanisms of streptococci. Mol Immunol (2003) 1.56
Activation of the alternative pathway of complement by monoclonal lambda light chains in membranoproliferative glomerulonephritis. J Exp Med (1992) 1.56
Surface-associated heparin inhibits zymosan-induced activation of the human alternative complement pathway by augmenting the regulatory action of the control proteins on particle-bound C3b. J Exp Med (1979) 1.53
C3b deposition during activation of the alternative complement pathway and the effect of deposition on the activating surface. J Immunol (1983) 1.52
The C-terminus of factor H: monoclonal antibodies inhibit heparin binding and identify epitopes common to factor H and factor H-related proteins. Biochem J (1998) 1.40
Complement C3b/C3d and cell surface polyanions are recognized by overlapping binding sites on the most carboxyl-terminal domain of complement factor H. J Immunol (2002) 1.32
Exceptional resistance of human H2 glioblastoma cells to complement-mediated killing by expression and utilization of factor H and factor H-like protein 1. J Immunol (2000) 1.30
The yeast Candida albicans binds complement regulators factor H and FHL-1. Infect Immun (2002) 1.28
Regulation of alternative pathway complement activation by glycosaminoglycans: specificity of the polyanion binding site on factor H. Biochem Biophys Res Commun (1994) 1.26
Human polymorphonuclear leukocytes adhere to complement factor H through an interaction that involves alphaMbeta2 (CD11b/CD18). J Immunol (1998) 1.23
Analysis of the ability of spirochete species associated with relapsing fever, avian borreliosis, and epizootic bovine abortion to bind factor H and cleave c3b. J Clin Microbiol (2003) 1.18
Inhibition of the alternative pathway of human complement by structural analogues of sialic acid. J Immunol (1988) 1.13
Analysis of the mechanism of recognition in the complement alternative pathway using C3b-bound low molecular weight polysaccharides. J Immunol (1989) 1.05
Complement C3b interactions studied with surface plasmon resonance technique. Int Immunopharmacol (2001) 0.99
Identification of the streptococcal M protein binding site on membrane cofactor protein (CD46). J Immunol (2002) 0.94
Complement factor H-binding protein of Raji cells and tonsil B lymphocytes. Biochem J (1987) 0.93
Release of endogenous anti-inflammatory complement regulators FHL-1 and factor H protects synovial fibroblasts during rheumatoid arthritis. Clin Exp Immunol (2003) 0.88
Truncated forms of human complement factor H. Biochem J (1989) 0.88
A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med (2009) 14.13
Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med (2009) 12.73
Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial. Lancet (2010) 7.69
Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease. N Engl J Med (2013) 7.54
Preventing microalbuminuria in type 2 diabetes. N Engl J Med (2004) 6.41
The contribution of chronic kidney disease to the global burden of major noncommunicable diseases. Kidney Int (2011) 6.21
Atypical hemolytic-uremic syndrome. N Engl J Med (2009) 5.66
Erythropoietic response and outcomes in kidney disease and type 2 diabetes. N Engl J Med (2010) 5.48
Lower estimated glomerular filtration rate and higher albuminuria are associated with mortality and end-stage renal disease. A collaborative meta-analysis of kidney disease population cohorts. Kidney Int (2011) 5.25
Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL. Kidney Int (2004) 4.51
Genetics of HUS: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome. Blood (2006) 4.51
Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype. Clin J Am Soc Nephrol (2010) 3.82
Rituximab in idiopathic membranous nephropathy. J Am Soc Nephrol (2012) 3.79
Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy. Circulation (2004) 3.78
Membranoproliferative glomerulonephritis type II (dense deposit disease): an update. J Am Soc Nephrol (2005) 3.57
Blood-pressure control for renoprotection in patients with non-diabetic chronic renal disease (REIN-2): multicentre, randomised controlled trial. Lancet (2005) 3.52
How does proteinuria cause progressive renal damage? J Am Soc Nephrol (2006) 3.46
Mesenchymal stem cells are renotropic, helping to repair the kidney and improve function in acute renal failure. J Am Soc Nephrol (2004) 3.41
Thrombomodulin mutations in atypical hemolytic-uremic syndrome. N Engl J Med (2009) 3.24
Hemolytic uremic syndrome. J Am Soc Nephrol (2005) 3.19
Early-childhood membranous nephropathy due to cationic bovine serum albumin. N Engl J Med (2011) 3.17
Sodium intake, ACE inhibition, and progression to ESRD. J Am Soc Nephrol (2011) 3.13
Glomeruli of Dense Deposit Disease contain components of the alternative and terminal complement pathway. Kidney Int (2009) 3.12
Delayed graft function in kidney transplantation. Lancet (2004) 3.06
New approaches to the treatment of dense deposit disease. J Am Soc Nephrol (2007) 3.02
Factor H-related protein 1 (CFHR-1) inhibits complement C5 convertase activity and terminal complex formation. Blood (2009) 2.97
Mutations in factor H reduce binding affinity to C3b and heparin and surface attachment to endothelial cells in hemolytic uremic syndrome. J Clin Invest (2003) 2.96
Decision time for pancreatic islet-cell transplantation. Lancet (2008) 2.91
Familial haemolytic uraemic syndrome and an MCP mutation. Lancet (2003) 2.79
Deletion of complement factor H-related genes CFHR1 and CFHR3 is associated with atypical hemolytic uremic syndrome. PLoS Genet (2007) 2.79
Complement factor H mutations and gene polymorphisms in haemolytic uraemic syndrome: the C-257T, the A2089G and the G2881T polymorphisms are strongly associated with the disease. Hum Mol Genet (2003) 2.71
Renal progenitors: an evolutionary conserved strategy for kidney regeneration. Nat Rev Nephrol (2013) 2.66
MYO1E mutations and childhood familial focal segmental glomerulosclerosis. N Engl J Med (2011) 2.65
Complement factor H binds malondialdehyde epitopes and protects from oxidative stress. Nature (2011) 2.64
Albuminuria is a target for renoprotective therapy independent from blood pressure in patients with type 2 diabetic nephropathy: post hoc analysis from the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial. J Am Soc Nephrol (2007) 2.61
Phosphate may promote CKD progression and attenuate renoprotective effect of ACE inhibition. J Am Soc Nephrol (2011) 2.60
Human bone marrow mesenchymal stem cells accelerate recovery of acute renal injury and prolong survival in mice. Stem Cells (2008) 2.51
Disruption of the Ang II type 1 receptor promotes longevity in mice. J Clin Invest (2009) 2.49
Role of remission clinics in the longitudinal treatment of CKD. J Am Soc Nephrol (2008) 2.48
Factor H autoantibodies in atypical hemolytic uremic syndrome correlate with CFHR1/CFHR3 deficiency. Blood (2007) 2.46
Immunosuppressive treatment for idiopathic membranous nephropathy: a systematic review. Am J Kidney Dis (2004) 2.43
Sirolimus therapy to halt the progression of ADPKD. J Am Soc Nephrol (2010) 2.42
Risk scores for predicting outcomes in patients with type 2 diabetes and nephropathy: the RENAAL study. Clin J Am Soc Nephrol (2006) 2.37
Safety and efficacy of long-acting somatostatin treatment in autosomal-dominant polycystic kidney disease. Kidney Int (2005) 2.32
MicroRNA-324-3p promotes renal fibrosis and is a target of ACE inhibition. J Am Soc Nephrol (2012) 2.26
Ameliorating hypertension and insulin resistance in subjects at increased cardiovascular risk: effects of acetyl-L-carnitine therapy. Hypertension (2009) 2.20
Pretransplant infusion of mesenchymal stem cells prolongs the survival of a semiallogeneic heart transplant through the generation of regulatory T cells. J Immunol (2008) 2.17
Timed urine collections are not needed to measure urine protein excretion in clinical practice. Am J Kidney Dis (2006) 2.17
Podocyte number in normotensive type 1 diabetic patients with albuminuria. Diabetes (2002) 2.12
Combined kidney and liver transplantation for familial haemolytic uraemic syndrome. Lancet (2002) 2.12
Albuminuria response to very high-dose valsartan in type 2 diabetes mellitus. J Hypertens (2007) 2.12
Complement inhibitor factor H binding to Lyme disease spirochetes is mediated by inducible expression of multiple plasmid-encoded outer surface protein E paralogs. J Immunol (2002) 2.06
Insulin-like growth factor-1 sustains stem cell mediated renal repair. J Am Soc Nephrol (2007) 2.02
Factor H family proteins and human diseases. Trends Immunol (2008) 2.02
Progression risk, urinary protein excretion, and treatment effects of angiotensin-converting enzyme inhibitors in nondiabetic kidney disease. J Am Soc Nephrol (2007) 2.00
Successful treatment of DEAP-HUS with eculizumab. Pediatr Nephrol (2013) 2.00
Y402H polymorphism of complement factor H affects binding affinity to C-reactive protein. J Immunol (2007) 2.00
Complement and the atypical hemolytic uremic syndrome in children. Pediatr Nephrol (2008) 1.99
Complement resistance of Borrelia burgdorferi correlates with the expression of BbCRASP-1, a novel linear plasmid-encoded surface protein that interacts with human factor H and FHL-1 and is unrelated to Erp proteins. J Biol Chem (2003) 1.99
Chronic renal diseases as a public health problem: epidemiology, social, and economic implications. Kidney Int Suppl (2005) 1.96
Factor H dysfunction in patients with atypical hemolytic uremic syndrome contributes to complement deposition on platelets and their activation. Blood (2008) 1.95
An imbalance of human complement regulatory proteins CFHR1, CFHR3 and factor H influences risk for age-related macular degeneration (AMD). Hum Mol Genet (2010) 1.95
Defective complement control of factor H (Y402H) and FHL-1 in age-related macular degeneration. Mol Immunol (2007) 1.94
Human factor H-related protein 5 has cofactor activity, inhibits C3 convertase activity, binds heparin and C-reactive protein, and associates with lipoprotein. J Immunol (2005) 1.92
Retarding progression of chronic renal disease: the neglected issue of residual proteinuria. Kidney Int (2003) 1.91
Proteasomal processing of albumin by renal dendritic cells generates antigenic peptides. J Am Soc Nephrol (2008) 1.89
STEC-HUS, atypical HUS and TTP are all diseases of complement activation. Nat Rev Nephrol (2012) 1.89
Streptococcus pneumoniae evades complement attack and opsonophagocytosis by expressing the pspC locus-encoded Hic protein that binds to short consensus repeats 8-11 of factor H. J Immunol (2002) 1.87
Autologous mesenchymal stromal cells and kidney transplantation: a pilot study of safety and clinical feasibility. Clin J Am Soc Nephrol (2010) 1.87
von Willebrand factor cleaving protease (ADAMTS13) is deficient in recurrent and familial thrombotic thrombocytopenic purpura and hemolytic uremic syndrome. Blood (2002) 1.85
Imaging of the porous ultrastructure of the glomerular epithelial filtration slit. J Am Soc Nephrol (2010) 1.85
Glomerular hyperfiltration and renal disease progression in type 2 diabetes. Diabetes Care (2012) 1.85
Implications of the initial mutations in membrane cofactor protein (MCP; CD46) leading to atypical hemolytic uremic syndrome. Mol Immunol (2006) 1.82
The GFR and GFR decline cannot be accurately estimated in type 2 diabetics. Kidney Int (2013) 1.81